Texas Permanent School Fund Cara Therapeutics, Inc. Transaction History

Texas Permanent School Fund

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 01, 2023	BUY	$4.89 - $12.27 $111,883 - $280,737	22,880 Added 89.32%	48,495 $238,000
Q4 2022 Feb 07, 2023	SELL	$8.88 - $12.77 $58,758 - $84,499	-6,617 Reduced 20.53%	25,615 $275,000
Q3 2022 Oct 25, 2022	BUY	$8.24 - $12.56 $15,804 - $24,090	1,918 Added 6.33%	32,232 $302,000
Q2 2022 Aug 08, 2022	BUY	$7.45 - $13.84 $4,693 - $8,719	630 Added 2.12%	30,314 $277,000
Q1 2022 May 06, 2022	SELL	$9.94 - $12.65 $7,594 - $9,664	-764 Reduced 2.51%	29,684 $361,000
Q4 2021 Feb 08, 2022	SELL	$11.99 - $18.14 $8,117 - $12,280	-677 Reduced 2.18%	30,448 $371,000
Q3 2021 Oct 28, 2021	SELL	$11.55 - $16.06 $11,007 - $15,305	-953 Reduced 2.97%	31,125 $481,000
Q2 2021 Jul 27, 2021	BUY	$12.38 - $29.19 $397,125 - $936,356	32,078 New	32,078 $458,000

12.8M

Ticker CARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,725,900
Market Cap $262M
Description
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...

Get notified when there are updates to the investment portfolio of Texas Permanent School Fund, based on Form 13F filings with the SEC.

Stay updated on Texas Permanent School Fund with notifications on news.